Wakiyama Yoshinari, Kumura Ko, Umemura Eijiro, Ueda Kazutaka, Watanabe Takashi, Yamada Keiko, Okutomi Takafumi, Ajito Keiichi
Pharmaceutical Research Center, Meiji Seika Pharma, Yokohama, Japan.
J Antibiot (Tokyo). 2017 Jul;70(8):888-906. doi: 10.1038/ja.2017.54. Epub 2017 May 31.
To modify lincomycin (LCM) at the C-6 and the C-7 positions, we firstly prepared various substituted proline intermediates (7, 11-15 and 17). These proline intermediates were coupled with methyl 1-thio-α-lincosamide and tetrakis-O-trimethylsilylation followed by selective deprotection of the TMS group at the 7-position gave a wide variety of key intermediates (23-27, 47 and 50). Then, we synthesized a variety of novel LCM analogs modified at the 7-position in application of the Mitsunobu reaction, an S2 reaction, and a Pd-catalyzed cross-coupling reaction. Compounds 34 and 35 (1'-NH derivatives) exhibited enhanced antibacterial activities against resistant pathogens with erm gene compared with the corresponding 1'-N-methyl derivatives (3 and 37). On the basis of reported SAR, we modified the 4'-position of LCM derivatives possessing a 5-(2-nitrophenyl)-1,3,4-thiadiazol-2-yl group at the C-7 position. Compound 56 showed significantly potent antibacterial activities against S. pneumoniae and S. pyogenes with erm gene, and its activities against S. pneumoniae with erm gene were improved compared with those of 34 and 57. Although we synthesized novel analogs by transformation of a C-7 substituent focusing on the 1'-demethyl framework to prepare very potent analogs 73 and 75, it was impossible to generate novel derivatives exhibiting stronger antibacterial activities against S. pneumoniae with erm gene compared with 56.
为了在林可霉素(LCM)的C-6和C-7位进行修饰,我们首先制备了各种取代的脯氨酸中间体(7、11 - 15和17)。这些脯氨酸中间体与1-硫代-α-林可酰胺甲酯偶联,然后进行四-O-三甲基硅烷基化,接着选择性脱除7位的TMS基团,得到了多种关键中间体(23 - 27、47和50)。然后,我们应用 Mitsunobu 反应、S2反应和钯催化的交叉偶联反应,合成了多种在7位修饰的新型LCM类似物。与相应的1'-N-甲基衍生物(3和37)相比,化合物34和35(1'-NH衍生物)对携带erm基因的耐药病原体表现出增强的抗菌活性。基于已报道的构效关系(SAR),我们对在C-7位具有5-(2-硝基苯基)-1,3,4-噻二唑-2-基的LCM衍生物的4'-位进行了修饰。化合物56对携带erm基因的肺炎链球菌和化脓性链球菌显示出显著的强效抗菌活性,并且其对携带erm基因的肺炎链球菌的活性比34和57有所提高。尽管我们通过转化C-7取代基,以1'-去甲基骨架为重点合成了新型类似物,制备了非常有效的类似物73和75,但与56相比,不可能生成对携带erm基因的肺炎链球菌表现出更强抗菌活性的新型衍生物。